Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association

Posted: June 4, 2022 at 2:45 am

Daix (France), Long Island City (New York, United States), June 3, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that the abstract “The Pan-PPAR agonist lanifibranor improves nonalcoholic steatohepatitis (NASH) and glycemic control” has been selected for poster presentation during the American Diabetes Association’s 82nd Scientific Sessions taking place on June 3-7, 2022 New Orleans, United States.

Original post:
 Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association

Related Posts